Xeljanz: FDA’s new warnings about an increased risk of blood clots
by Press Release from Outbreak News Today on (#4M55B)
On Friday, the Food and Drug Administration (FDA) approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of Xeljanz, Xeljanz XR (tofacitinib), which is used in patients with ulcerative colitis. In addition, the approved use of tofacitinib for ulcerative colitis will be limited to ["]
The post Xeljanz: FDA's new warnings about an increased risk of blood clots appeared first on Outbreak News Today.